Cargando…

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer

BACKGROUND: Cetuximab, a monoclonal antibody against EGFR used for the treatment of colorectal cancer (CRC), is ineffective in many patients. The aim of this study was to identify the signalling pathways activated by cetuximab in CRC cells and define new biomarker of response. METHODS: We used in vi...

Descripción completa

Detalles Bibliográficos
Autores principales: Marzi, L, Combes, E, Vié, N, Ayrolles-Torro, A, Tosi, D, Desigaud, D, Perez-Gracia, E, Larbouret, C, Montagut, C, Iglesias, M, Jarlier, M, Denis, V, Linares, L K, Lam, E W-F, Martineau, P, Del Rio, M, Gongora, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104890/
https://www.ncbi.nlm.nih.gov/pubmed/27685445
http://dx.doi.org/10.1038/bjc.2016.313

Ejemplares similares